Most Read Articles
Christina Lau, 2 days ago
Progress in the treatment of rare cancers is named Advance of the Year by the American Society of Clinical Oncology (ASCO).
Jackey Suen, 08 Jul 2016

Scientists have refined anti-CD19 chimeric antigen receptor (CAR) T cell therapy, an investigational treatment for advanced non-Hodgkin’s lymphoma, with initial results showing significantly higher response and survival rates than the standard repertoire.

SBRT reduces acute toxicities in Asians with early-stage prostate cancer

Christina Lau
28 Nov 2018
Dr Darren Poon

Stereotactic body radiotherapy (SBRT) is associated with significantly lower rates of acute gastrointestinal (GI) and genitourinary (GU) toxicities compared with conventional fractionated intensity-modulated radiotherapy (CF-IMRT) in Asian patients with early-stage localized prostate cancer.

These results, from a randomized phase II study (n=64) reported at the European Society for Medical Oncology (ESMO) Asia 2018 Congress, suggest that SBRT (5 fractions) is a safe treatment option for Asians with low- or intermediate-risk localized prostate cancer when compared with CF-IMRT (38 fractions). [Poon DMC, et al, ESMO Asia 2018, abstract 218P]

“Patients in the SBRT group had significantly lower rates of grade ≥1 acute GI toxicities and grade ≥2 acute GU toxicities than those in the CF-IMRT group [35 percent vs 87 percent (p<0.0001) and 3 percent vs 24 percent (p=0.0426), respectively],” reported Dr Darren Poon of the Chinese University of Hong Kong. “No grade ≥3 acute toxicities were reported in either group.”
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Christina Lau, 2 days ago
Progress in the treatment of rare cancers is named Advance of the Year by the American Society of Clinical Oncology (ASCO).
Jackey Suen, 08 Jul 2016

Scientists have refined anti-CD19 chimeric antigen receptor (CAR) T cell therapy, an investigational treatment for advanced non-Hodgkin’s lymphoma, with initial results showing significantly higher response and survival rates than the standard repertoire.